IGF-1 down-regulates IFN-γR2 chain surface expression and desensitizes IFN-γ/STAT-1 signaling in human T lymphocytes

被引:41
作者
Bernabei, P
Bosticardo, M
Losana, G
Regis, G
Di Paola, F
De Angelis, S
Giovarelli, M
Novelli, F
机构
[1] San Giovanni Battista Hosp, CeRMS, I-10126 Turin, Italy
[2] Univ Turin, Dept Clin & Biol Sci, Orbassano, Italy
关键词
D O I
10.1182/blood-2003-01-0100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ability of insulin-like growth factor-1 (IGF-1) to regulate surface expression of the interferon-gamma receptor 2 (IFN-gammaR2) transducing chain and activation of IFN-gamma-induced signal transducer and activator of transcription-1 (STAT-1) in human T cells was analyzed. We show that, especially in the absence of serum (which contains IGF-1), IGF-1 down-regulated surface expression of the IFN-gammaR2 chain and inhibited both IFN-gamma-depenclent STAT-1 activation and apoptosis in T-cell lines ST4, Jurkat, and Molt-4. IFN-gammaR2 down-regulation resulted from its enhanced internalization since IGF-1 completely restored the uptake of anti-IFN-gammaR2 monoclonal antibody (mAb) in serum-deprived T-cell lines. When the interaction between IGF-1 and its receptor was blocked by anti-IGF-1R mAb, enhancement of IFN-gammaR2 surface expression, STAT-1 activation, and reinstatement of IFN-gamma-induced apoptosis were observed. Enhanced expression of IFN-gammaR2 was also observed in phytohemagglutinin (PHA)-activated T lymphoblasts cultured in the presence of anti-IGF-1R mAb, whereas IGF-1 or anti-IGF-1R mAb did not modify the high IFN-gammaR2 expression in B and myeloid cell lines. Both IGF-1 and anti-IGF-1 R mAb did not modify the constitutive expression of IFN-gammaR2 mRNA in T cells as well as the high IFN-gammaR1 binding chain surface expression in T, B, and myeloid cells. These data indicate that IGF-1 plays a critical role in the desensitization of IFN-gamma/STAT-1 signaling in T lymphocytes by delivering a signal for IFN-gammaR2 internalization. (Blood. 2003;102: 2933-2939) (C) 2003 by The American Society of Hematology.
引用
收藏
页码:2933 / 2939
页数:7
相关论文
共 48 条
[31]  
NOVELLI F, 1994, J IMMUNOL, V152, P496
[32]   LACK OF INTERFERON-GAMMA RECEPTOR-BETA CHAIN AND THE PREVENTION OF INTERFERON-GAMMA SIGNALING IN T(H)1 CELLS [J].
PERNIS, A ;
GUPTA, S ;
GOLLOB, KJ ;
GARFEIN, E ;
COFFMAN, RL ;
SCHINDLER, C ;
ROTHMAN, P .
SCIENCE, 1995, 269 (5221) :245-247
[33]  
Pestka Sidney, 1997, Cytokine and Growth Factor Reviews, V8, P189, DOI 10.1016/S1359-6101(97)00009-9
[34]   Interferon γ is required for activation-induced death of T lymphocytes [J].
Refaeli, Y ;
Van Parijs, L ;
Alexander, SI ;
Abbas, AK .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :999-1005
[35]   Surface expression of the IFN-γR2 chain is regulated by intracellular trafficking in human T lymphocytes [J].
Rigamonti, L ;
Ariotti, S ;
Losana, G ;
Gradini, R ;
Russo, MA ;
Jouanguy, E ;
Casanova, JL ;
Forni, G ;
Novelli, F .
JOURNAL OF IMMUNOLOGY, 2000, 164 (01) :201-207
[36]   Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3 [J].
Sato, T ;
Selleri, C ;
Young, NS ;
Maciejewski, JP .
BLOOD, 1997, 90 (12) :4749-4758
[37]   Downregulation of insulin-like growth factor-1 receptor (IGF-1R) expression in human T lymphocyte activation [J].
Schillaci, R ;
Brocardo, MG ;
Galeano, A ;
Roldan, A .
CELLULAR IMMUNOLOGY, 1998, 183 (02) :157-161
[38]   IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity [J].
Shankaran, V ;
Ikeda, H ;
Bruce, AT ;
White, JM ;
Swanson, PE ;
Old, LJ ;
Schreiber, RD .
NATURE, 2001, 410 (6832) :1107-1111
[39]   Ligand-independent down-regulation of IFN-γ receptor 1 following TCR engagement [J].
Skrenta, H ;
Yang, Y ;
Pestka, S ;
Fathman, CG .
JOURNAL OF IMMUNOLOGY, 2000, 164 (07) :3506-3511
[40]   INSULIN-LIKE GROWTH FACTOR-I BINDS SELECTIVELY TO HUMAN PERIPHERAL-BLOOD MONOCYTES AND LYMPHOCYTE-B [J].
STUART, CA ;
MEEHAN, RT ;
NEALE, LS ;
CINTRON, NM ;
FURLANETTO, RW .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (05) :1117-1122